secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0000950170-25-007532
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology appoints Harish Shantharam as CFO and adds Klencke, Takimoto to board
--------------------------------------------------------------------------------

- Harish Shantharam named CFO effective Jan 21, 2025; base salary $490k, target bonus 40%, option for 600k shares.
- Barbara Klencke, M.D. and Chris Takimoto, M.D., Ph.D. appointed to Board effective Jan 18, 2025; each receives initial option for 40,400 shares.
- Shantharam previously CFO of CymaBay ($4.3B Gilead acquisition); held finance roles at Gilead and Amgen.
- Klencke serves on boards of Xencor, TScan, Immune-Onc; Takimoto is CMO at START Center, former CMO at Forty Seven ($4.9B Gilead acquisition).
- Board expanded to 6 members; new committee assignments: Klencke on Audit/R&D, Takimoto on Compensation/R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/0000950170-25-007532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017025007532/alxo-20250116.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-007532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer